PacBio Files 8-K: Operations, Costs, and Financials

Ticker: PACB · Form: 8-K · Filed: 2024-04-16T00:00:00.000Z

Sentiment: neutral

Topics: financial-results, operations, disposal-costs

Related Tickers: PACB

TL;DR

PacBio dropped an 8-K on April 16th covering financials and operational updates.

AI Summary

On April 16, 2024, Pacific Biosciences of California, Inc. filed an 8-K report detailing financial results and other events. The filing includes information on the company's operations, costs associated with exits or disposals, and financial statements. Specific financial figures and operational details are expected to be elaborated upon within the full report.

Why It Matters

This 8-K filing provides crucial updates on Pacific Biosciences' financial condition and operational activities, which can impact investor decisions and market perception.

Risk Assessment

Risk Level: medium — 8-K filings can contain significant financial and operational information that may lead to stock price volatility.

Key Players & Entities

FAQ

What specific financial results are being reported in this 8-K?

The filing indicates it covers 'Results of Operations and Financial Condition' and 'Financial Statements and Exhibits', suggesting detailed financial results are included, though specific figures are not in the provided header.

What kind of 'Costs Associated with Exit or Disposal Activities' are mentioned?

The filing lists 'Cost Associated with Exit or Disposal Activities' as an item, but the nature and amount of these costs are not specified in the provided header.

Are there any significant 'Other Events' reported?

The filing notes 'Other Events' as a category, but no specific events are detailed in the provided header information.

When was Pacific Biosciences of California, Inc. incorporated?

The company's state of incorporation is listed as Delaware.

What is the primary business of Pacific Biosciences of California, Inc. according to the SIC code?

The Standard Industrial Classification (SIC) code provided is 3826, which corresponds to 'Laboratory Analytical Instruments'.

From the Filing

0001104659-24-047511.txt : 20240416 0001104659-24-047511.hdr.sgml : 20240416 20240416080831 ACCESSION NUMBER: 0001104659-24-047511 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20240416 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Cost Associated with Exit or Disposal Activities ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240416 DATE AS OF CHANGE: 20240416 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PACIFIC BIOSCIENCES OF CALIFORNIA, INC. CENTRAL INDEX KEY: 0001299130 STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 161590339 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-34899 FILM NUMBER: 24846149 BUSINESS ADDRESS: STREET 1: 1305 O'BRIEN DRIVE CITY: MENLO PARK STATE: CA ZIP: 94025 BUSINESS PHONE: 650-521-8000 MAIL ADDRESS: STREET 1: 1305 O'BRIEN DRIVE CITY: MENLO PARK STATE: CA ZIP: 94025 FORMER COMPANY: FORMER CONFORMED NAME: PACIFIC BIOSCIENCES OF CALIFORNIA INC DATE OF NAME CHANGE: 20050829 FORMER COMPANY: FORMER CONFORMED NAME: NANOFLUIDICS INC DATE OF NAME CHANGE: 20040729 8-K 1 tm2411926d1_8k.htm FORM 8-K false 0001299130 0001299130 2024-04-16 2024-04-16 iso4217:USD xbrli:shares iso4217:USD xbrli:shares       UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549   FORM 8-K   CURRENT REPORT   Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934   Date of Report (Date of earliest event reported) April 16, 2024   Pacific Biosciences of California, Inc. (Exact name of registrant as specified in its charter)   Delaware   001-34899   16-1590339 (State or other jurisdiction of incorporation)   (Commission File Number)   (IRS Employer Identification No.)   1305 O’Brien Drive Menlo Park , California 94025 (Address of principal executive offices) (Zip Code)   ( 650 ) 521-8000 (Registrant’s telephone number, including area code)   (Former name or former address, if changed since last report)   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):   ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Stock, par value $0.001 per share   PACB   The NASDAQ Stock Market LLC   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 ( §230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).   Emerging growth company ¨   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨           ITEM 2.02. RESULTS OF OPERATIONS AND FINANCIAL CONDITION.   On April 16, 2024, Pacific Biosciences of California, Inc. (the “Company”) issued a press release providing a business update and announcing certain unaudited preliminary financial results a

View on Read The Filing